Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
16 results
  • Breast Cancer, Cervical Cancer, Head and Neck Cancer, Ovarian Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Breast Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Thyroid Cancer, Sarcoma

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Lymphoma, Lung Cancer, Head and Neck Cancer, Melanoma

21-258          Phase II

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab

  • Bladder Cancer, Melanoma, Head and Neck Cancer, Lung Cancer

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Breast Cancer, Head and Neck Cancer, Esophageal Cancer, Cervical Cancer, Lung Cancer, Ovarian Cancer

22-281          Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors

  • Head and Neck Cancer, Lung Cancer, Thyroid Cancer

22-124          Phase I

A Phase 1 Study of Oral LOXO-260 in Patients with RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation Refractory to Selective RET Inhibitors

  • Thyroid Cancer, Lung Cancer, Head and Neck Cancer

17-241          Phase I

A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)

  • Esophageal Cancer, Melanoma, Pancreatic Cancer, Ovarian Cancer, Breast Cancer, Colorectal Cancer, Gastric (Stomach) Cancer, Head and Neck Cancer, Lung Cancer

22-601          Phase II

A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers

  • Lung Cancer, Kidney Cancer, Head and Neck Cancer, Ovarian Cancer, Melanoma, Breast Cancer, Bladder Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

  • Ovarian Cancer, Colorectal Cancer, Lung Cancer, Kidney Cancer, Head and Neck Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Rectal Cancer, Thymoma, Melanoma

23-423          Phase I

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination with Tislelizumab in Patients with Select Advanced Cancers

Showing 1 - 10 of 16 results